What Is Wet AMD?
Wet age-related macular degeneration (Wet AMD) is a condition that affects the central portion of the retina known as the macula, which is responsible for sharp, detailed vision used for reading, driving, and recognizing faces.
In Wet AMD, abnormal blood vessels grow beneath the retina and may leak fluid or blood. Over time, this can damage the macula and lead to changes in central vision. Wet AMD typically develops later in life and may progress more rapidly than other forms of macular degeneration.
Early detection and treatment are important to help preserve vision.
Common Symptoms
Symptoms of Wet AMD may include:
-
Blurred or distorted central vision
-
Straight lines appearing wavy
-
Dark or missing spots in central vision
-
Difficulty reading or recognizing faces
-
Reduced ability to see fine details
-
Changes in color or contrast perception
If you experience sudden changes in vision, it is important to contact an eye care professional promptly.
Why Clinical Trials Matter
Clinical trials help researchers evaluate new therapies and treatment approaches that may improve outcomes for patients living with retinal diseases such as Wet AMD.
Participation in a clinical trial may provide access to investigational treatments and contributes to ongoing research aimed at advancing future care options. Each study has specific eligibility requirements, and participation is always voluntary.
Study name
4FRONT-2 | Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
​
Sponsor
4D Molecular Therapeutics
​
Study details
The 4FRONT-2 study is a Phase 3 study that will test an investigational gene therapy (also known as a “study drug”) called 4D-150 to see if it is effective, safe, and if it reduces the number of injections in comparison to the standard treatment in people with wet AMD.
Who can participate
For people who have been diagnosed with wet AMD but have not yet been treated for wet AMD in the affected eye, OR have been diagnosed with wet AMD within the past six months and have not received more than four injections for wet AMD treatment in the affected eye.
​
Study name:
An Evaluation of the Clinical Usability of the SCD411 Prefilled Syringe as a Proposed Biosimilar to US-licensed Eylea®
Sponsor: Sam Chun Dang
Study details
This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), or Diabetic Retinopathy (DR)
Who can participate
Participants must be 18 years or older with a confirmed diagnosis of neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, or Diabetic Retinopathy (uni- or bilateral).